Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [6]. Core Views - The company has demonstrated strong profitability resilience despite a decline in metal prices, with cobalt, nickel, and lithium margins reaching historical lows. The current price levels provide a foundation for potential increases, which could significantly boost the company's performance [7][9]. - The company has established a comprehensive business structure with five major sectors: new energy, new materials, Indonesian nickel, African resources, and recycling [13][16]. - The report highlights the cyclical nature of metal prices, indicating that cobalt prices are at a long-term historical low, with potential for substantial increases due to demand growth and supply constraints [33][51]. Summary by Sections Market Performance - As of April 28, 2025, the closing price of the company's stock is 33.36 yuan, with a market capitalization of approximately 56.76 billion yuan [4]. Financial Forecast and Valuation - The projected revenue for 2023 is 66.30 billion yuan, with a forecasted decline to 60.95 billion yuan in 2024, followed by a recovery to 70.44 billion yuan in 2025. The net profit attributable to the parent company is expected to rise from 3.35 billion yuan in 2023 to 5.07 billion yuan in 2025 [6][8]. - The report anticipates a price-to-earnings (P/E) ratio of 11.19 for 2025, which is below the industry average, indicating potential undervaluation [8]. Investment Logic - The company has maintained stable revenue and profitability despite fluctuations in metal prices, with nickel and lithium segments showing growth while cobalt has declined. The overall business structure is resilient, with significant upside potential if metal prices recover [20][29]. - The report emphasizes that the current low prices of cobalt, nickel, and lithium create a favorable environment for future price increases, which could enhance the company's earnings significantly [7][9]. Cobalt Market Insights - Cobalt prices are currently at a long-term low, with expectations for a significant rebound driven by demand growth and supply constraints, particularly from the Democratic Republic of Congo [33][51]. - The report notes that the recent export ban from the Democratic Republic of Congo could further tighten supply, enhancing the potential for price increases [36]. Nickel Market Insights - Nickel supply is dominated by Indonesia, which is expected to account for 60% of global production in 2024. The report indicates that while supply is increasing, rising costs and the closure of high-cost mines may stabilize prices [53][60]. Lithium Market Insights - The lithium market is experiencing a supply-demand mismatch, with prices at historical lows. The report forecasts that the price of lithium carbonate will stabilize around 80,000 yuan per ton in 2025, with potential for increases as demand recovers [67][72].

证券研究报告 机械设备 | 通用设备 非金融|首次覆盖报告 hyzqdatemark 2025 年 04 月 29 日 戴铭余 SAC：S1350524060003 daimingyu@huayuanstock.com 王彬鹏 SAC：S1350524090001 wangbinpeng@huayuanstock.com 郦悦轩 SAC：S1350524080001 liyuexuan@huayuanstock.com 唐志玮 tangzhiwei@huayuanstock.com 林高凡 lingaofan@huayuanstock.com | 基本数据 | | | | 2025 | 年 | 04 | 28 | 日 | 月 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 收盘价（元） | | | | | | | | | | | | 51.68 | | 一 年 最 低 | 最 | 高 | / | | | | | | | 53.88/18.22 | 内 | | | （元） | | ...

证券研究报告 机械设备 | 通用设备 北交所|首次覆盖报告 hyzqdatemark 2025 年 04 月 29 日 证券分析师 赵昊 SAC：S1350524110004 zhaohao@huayuanstock.com 万枭 SAC：S1350524100001 wanxiao@huayuanstock.com 市场表现： | 基本数据 | | 年 | | 月 | | 04 | | | | 29 日 | | 2025 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 收盘价（元） | | | | | | | | | | 14.10 | | | | 一 年 | 内 | | 高 | | 18.60/6.00 | | 最 | / | 最 | | 低 | | | （元） | | | | | | | | | | | | | | 总市值（百万元） | | | | | 1,192.58 | | | | | | | | | 流通市值（百万元） | | | | | | | | | | 884.80 | | ...

证券研究报告 公用事业 | 燃气Ⅱ 非金融|公司点评报告 hyzqdatemark 2025 年 04 月 29 日 证券分析师 查浩 SAC：S1350524060004 zhahao@huayuanstock.com 刘晓宁 SAC：S1350523120003 liuxiaoning@huayuanstock.com 市场表现： | 基本数据 | 年 | 04 | 月 28 | 日 | | 2025 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 收盘价（元） | | | 6.43 | | | | | | 内 高 | | | 8.30/6.15 | | / | | | | （元） | | | | | | | | | 总市值（百万元） | | | 18,497.44 | | | | | | 流通市值（百万元） | | | 18,497.44 | | | | | | 总股本（百万股） | | | 2,876.74 | | | | | | 资产负债率（%） | | | 58.76 | | | | | | 每股净资产（元/股） | | | 5.41 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is experiencing rapid growth in overseas business and optimizing its global installed structure [5] - Revenue forecasts for 2025-2027 are projected at 51.63 billion, 59.61 billion, and 69.28 billion RMB, with year-on-year growth rates of 13.84%, 15.45%, and 16.22% respectively [6] - Net profit attributable to the parent company for the same period is expected to be 20.12 billion, 23.43 billion, and 27.38 billion RMB, with growth rates of 10.06%, 16.41%, and 16.85% respectively [6] - The current price-to-earnings (P/E) ratios are 21x, 18x, and 15x for the years 2025, 2026, and 2027 [6] Financial Performance Summary - In 2024, the company achieved a revenue of 45.35 billion RMB (yoy +15.41%) and a net profit of 18.28 billion RMB (yoy +10.57%) [8] - For Q1 2025, the company reported a revenue of 11.25 billion RMB (yoy +10.12%) and a net profit of 4.38 billion RMB (yoy +2.65%) [8] - The company’s gross margin for 2024 was 72.26%, a slight decrease of 0.86 percentage points year-on-year, primarily due to an increase in the sales proportion of large and medium-sized instruments [8] - The company plans to continue increasing its investment in chemiluminescence and in vitro diagnostic products, with the launch of higher throughput instruments [8] Market Position and Strategy - The company has established operational systems in 14 core countries overseas, with significant sales growth in the Indian market, which exceeded 200 million RMB in 2024 [8] - The domestic revenue reached 28.43 billion RMB in 2024, with a year-on-year growth of 9.32%, driven by the promotion of high-speed instruments and production lines [8] - The company aims to enhance its market share in large medical institutions, achieving a coverage rate of 44.93% in tertiary hospitals by the end of 2024 [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company has successfully advanced its new brand collaborations, with Q1 2025 revenue growth meeting expectations [5] - In Q1 2025, the company achieved revenue of 5.353 billion RMB, a year-on-year increase of 12.34%, while the net profit attributable to shareholders was 762 million RMB, a decrease of 3.25% [7] - The company continues to deepen cooperation with new clients and emerging sports brands, with sales of sports shoes reaching 49 million pairs, up 8.24% year-on-year [7] - The company has a strong dividend policy, distributing 2.3 RMB per share (including tax) for the 2024 fiscal year, with an expected payout ratio of approximately 70% of net profit [7] - The company is expanding its production capacity to meet downstream demand, with two new shoe factories starting operations in Q1 2025, increasing the workforce to 184,000, a year-on-year increase of 17% [7] - The growth in orders is driven by increased consumer demand in the sports industry and deeper collaborations with brands like Adidas [7] - The company is expected to see a rise in average selling price (ASP) due to structural changes in its client base [7] Financial Summary - Revenue projections for the company are as follows: - 2023: 20.114 billion RMB - 2024: 24.006 billion RMB (19.35% YoY growth) - 2025E: 27.664 billion RMB (15.24% YoY growth) - 2026E: 31.734 billion RMB (14.71% YoY growth) - 2027E: 36.258 billion RMB (14.25% YoY growth) [6] - Net profit projections are as follows: - 2023: 3.2 billion RMB - 2024: 3.84 billion RMB (20% YoY growth) - 2025E: 4.355 billion RMB (13.4% YoY growth) - 2026E: 4.959 billion RMB (13.87% YoY growth) - 2027E: 5.731 billion RMB (15.58% YoY growth) [6] - The company maintains a strong return on equity (ROE) of approximately 21% over the forecast period [6]

证券研究报告 医药生物 | 医疗器械 非金融|公司点评报告 hyzqdatemark 2025 年 04 月 29 日 投资要点： 联系人 梁裕 liangyu@huayuanstock.com 市场表现： 鱼跃医疗(002223.SZ) 投资评级： 买入（维持） ——收入回归稳健增长轨道，海外高速增长 证券分析师 刘闯 SAC：S1350524030002 liuchuang@huayuanstock.com | 基本数据 | | | | 年 | 04 | | 日 | 月 | | | 28 | 2025 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 收盘价（元） | | | | | | 34.43 | | | | | | | | 一 年 低 | 最 | 高 | / | | | 42.08/30.05 | | | 最 | 内 | | | | （元） | | | | | | | | | | | | | | 总市值（百万元） | | | | | | 34,515.28 | | | | | | ...

证券研究报告 基础化工 | 化学制品 非金融|公司点评报告 hyzqdatemark 2025 年 04 月 29 日 证券分析师 戴铭余 SAC：S1350524060003 daimingyu@huayuanstock.com 王彬鹏 SAC：S1350524090001 wangbinpeng@huayuanstock.com 郦悦轩 SAC：S1350524080001 liyuexuan@huayuanstock.com 林高凡 lingaofan@huayuanstock.com 唐志玮 tangzhiwei@huayuanstock.com | 基本数据 | | | 年 | 04 | 月 | | 日 | 2025 | 28 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 收盘价（元） | | | | | | 12.13 | | | | | 一 年 内 最 低 | 高 | / | | | | | | | | | （元） | | | | | | | | | | | 总市值（百万元） | | | | | | 7,535 ...

证券研究报告 交通运输 | 铁路公路 非金融|公司点评报告 hyzqdatemark 2025 年 04 月 29 日 招商公路(001965.SZ) 投资评级： 买入（维持） ——费用优化及投资收益增加，归母净利润同比改善 投资要点： | 盈利预测与估值（人民币） | | | | | | | --- | --- | --- | --- | --- | --- | | | 2023 | 2024 | 2025E | 2026E | 2027E | | 营业收入（百万元） | 9,731 | 12,711 | 12,895 | 13,230 | 13,600 | | 同比增长率（%） | 17.29% | 30.62% | 1.45% | 2.59% | 2.80% | | 归母净利润（百万元） | 6,767 | 5,322 | 5,735 | 6,186 | 6,704 | | 同比增长率（%） | 39.21% | -21.35% | 7.75% | 7.87% | 8.37% | | 每股收益（元/股） | 0.99 | 0.78 | 0.84 | 0.91 | 0.98 | | ROE（%） | 10 ...

电子 | 消费电子 北交所|首次覆盖报告 hyzqdatemark 2025 年 04 月 29 日 证券研究报告 证券分析师 赵昊 SAC：S1350524110004 zhaohao@huayuanstock.com 万枭 SAC：S1350524100001 wanxiao@huayuanstock.com 市场表现： | 基本数据 | 月 | | 年 | 04 | | 日 | | 25 | | 2025 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 收盘价（元） | | | | | 28.32 | | | | | | | 年 最 高 最 低 | | / | | | | | 一 | | | | | （元） | | | | | | | | | | | | 总市值（百万元） | | | | | 2,284.79 | | | | | | | 流通市值（百万元） | | | | | 1,250.57 | | | | | | | 总股本（百万股） | | | | | 80.68 | | | | | | | 资产负债率 ...